WHAT NEXT FOR OVOCA BIO INVESTORS?

Tim McCutcheon

IN A surprise move after the failure of the clinical trials for Ovoca Bio’s Orenetide drug, the CEO, Kirill Golovanov, resigned last week. More surprising, perhaps. was the decision of American non-executive director Tim McCutcheon (previously a CEO of the company in its Ovoca Gold iteration) to step in as Golovanov’s replacement and also to… Read more »

I'm a Subscriber